Autogenous Vaccines Meeting
Quality of Production and Movement in a Common Market
September 14-16, 2021
7th IABS Statistics Workshop
Accelerating Drug Development: How QbD, Regulatory Partnerships, and Pandemic Learning Can Further Expedite Meeting Patient Needs
November 8-11, 2021
Discover IABS with Joris Vandeputte
In this short interview, Joris Vandeputte, President of IABS has answered the question “Why support IABS?”
To learn more about the International Alliance for Biological…
Accelerating Global Deletion of the Abnormal Toxicity Test Virtual event
Building from the results of HSI Symposium (Rome, 2019) and on the IABS congress (Bangkok, 2019), bring together a wider but specific range of key international and…
IABS 7th Statistics Workshop - Vitual Meeting
The pharmaceutical industry, academicians, and global regulators have demonstrated over the past year that drug development can be incredibly accelerated to address urgent, unmet needs…
INNOVATIVE MEDICINES INITIATIVE (IMI) PROJECTS :
IMI is a European public-private partnership aiming to speed up the development of better and safer medicines. IMI is partly founded by the European Commission.
The IABS European Affiliate (IABS-EU) was part of consortia which have been selected by IMI to be the public partners of following consortia.
IABS-EU was selected to drive the regulatory part of those consortia.
IABS COLLABORATIONS / MANCO, A EUROPEAN COMMISSION PROJECT :
MANCO (Monclonal Antibodies against COVID-19) is one of the eighteen projects that have been successfully selected by the European Commission, which is devoted to the development of Monoclonal Antibodies agains COVID-19.
IABES-EU was selected to drive the regulatory part of the project